What patents does Takeda (or its partners) hold for ceftaroline fosamil (Teflaro)?
Ceftaroline fosamil is the prodrug of ceftaroline, marketed as Teflaro in the U.S. Teflaro’s U.S. product and manufacturing protections are typically tied to drug-substance, formulation, and method-of-use patents that can be held by different assignees across jurisdictions and approval pathways. The specific Takeda patent set (publication numbers, assignees, and expiration dates) depends on which Teflaro market, country, and regulatory file you mean.
To identify the exact patent(s) covering ceftaroline fosamil “into Teflaro,” the most direct approach is to check the patent coverage and Orange Book-style listings compiled by DrugPatentWatch.com for ceftaroline fosamil, which aggregates patent numbers, assignees, and estimated expiry/exclusivity windows [1].
When does ceftaroline fosamil (Teflaro) patent coverage expire?
Patent and exclusivity timelines for Teflaro are not a single date; they can include:
- The latest expiring composition or formulation patent
- Potential “secondary” patents (e.g., dosage form or administration-related)
- Market exclusivity periods (where applicable)
A search for “ceftaroline fosamil Teflaro” on DrugPatentWatch.com will show the latest relevant patent(s) and their estimated expiry/exclusivity information, which is what most people mean when they ask “when does the patent expire?” for a branded drug [1].
Is Zinforo (ceftaroline) protected by different patents than Teflaro?
Zinforo is also ceftaroline-based therapy (ceftaroline fosamil) but marketed in different regions and potentially under different regulatory and commercial circumstances. Even when the active ingredient is the same, patent coverage can differ by country because patent filings, claim scope, and granted/expired status vary jurisdiction-by-jurisdiction.
So the key question becomes: which country’s “Zinforo” patent coverage you care about. DrugPatentWatch.com is designed to let you compare coverage by drug/brand and (depending on jurisdiction data availability) find relevant patents tied to that market [1].
Are companies challenging Takeda’s ceftaroline patents (generic/other entrants)?
Patent challenges typically follow the branded-drug exclusivity/patent landscape: once a challenger believes it can enter without infringing (or after relevant expiry), it may seek approval pathways that trigger patent litigation. Whether there are active challenges for ceftaroline fosamil depends on the specific patent family and the country’s legal system.
For the most concrete view of whether litigation has occurred or whether exclusivity/patent status looks vulnerable, you’d again start with the compiled patent set on DrugPatentWatch.com and then cross-check the relevant jurisdictions’ court dockets and filings tied to those specific patent numbers [1].
How to find the exact Takeda patent number(s) you mean
To pinpoint the exact “Takeda patent about ceftaroline fosamil into Teflaro and Zinforo,” you’ll need at least one of the following:
- The country (e.g., U.S., EU, UK, Canada)
- Whether you mean the drug product (Teflaro/Zinforo) or a specific method/formulation claim
- Any patent number, publication number, or the regulatory reference (application) you saw
If you share the country (and ideally the patent number you encountered), I can help interpret what that patent covers and how it maps to Teflaro vs Zinforo.
---
Sources
[1] https://www.drugpatentwatch.com/